16,405 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Bought by Cibc World Markets Corp

Cibc World Markets Corp bought a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 16,405 shares of the company’s stock, valued at approximately $28,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the 4th quarter worth about $31,000. Intech Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies during the third quarter valued at approximately $85,000. Commonwealth Equity Services LLC raised its holdings in shares of Taysha Gene Therapies by 110.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company’s stock valued at $102,000 after acquiring an additional 31,000 shares during the period. MetLife Investment Management LLC boosted its stake in Taysha Gene Therapies by 81.9% in the 3rd quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after purchasing an additional 34,243 shares during the period. Finally, Franklin Resources Inc. acquired a new position in Taysha Gene Therapies in the 3rd quarter worth approximately $201,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Analysts Set New Price Targets

TSHA has been the topic of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $1.93 on Friday. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $4.32. The stock’s 50-day moving average is $1.65 and its two-hundred day moving average is $1.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The firm has a market cap of $395.65 million, a P/E ratio of 3.06 and a beta of 0.91.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. Analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.